Replies to post #501052 on NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

10/5/20 was the date trial data was unblinded, followed in five months that NWBO realized they failed the primary endpoint and reported they were changing the protocol, endpoints, comparator and SAP. Then they took a whole year of data dredging to come up with a new treatment arm (rGBM) that was never in the original trial.

The OS data is still confounded -- most of the patients had multiple doses of DCVax-L while any external trial would have had well-controlled trials. But NWBO's was not. It is clear confounding that very likely skewed the trial results in their favor because of the extra dosing. It's not opinion it is fact -- the trial protocol, NWBO SEC filings reported it.

[danielboog2]

Again, the facts are clear, and NWBO will persevere and be able to help many cancer patients who are the ones that will benefit from DCVax-L.

Hopefully, society will enormously benefit with the use of DC Vax....Some Day.
However by any measure NWBO has disappointedly under performed for a long time. Amazing how this board is suddenly without posts hyping a Journal. Apparently a reality of many years under performing has "reared its ugly head". I wish it were different.